GAMMA Investing LLC lifted its stake in shares of ICON Public Limited (NASDAQ:ICLR - Free Report) by 15,701.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 68,421 shares of the medical research company's stock after purchasing an additional 67,988 shares during the quarter. GAMMA Investing LLC owned about 0.08% of ICON Public worth $119,730,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also made changes to their positions in ICLR. Entropy Technologies LP raised its position in shares of ICON Public by 472.2% during the 4th quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company's stock worth $1,295,000 after purchasing an additional 5,095 shares during the period. Sierra Ocean LLC acquired a new stake in ICON Public in the 4th quarter valued at approximately $29,000. Kornitzer Capital Management Inc. KS increased its position in ICON Public by 40.6% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company's stock valued at $20,363,000 after acquiring an additional 28,050 shares during the period. FDx Advisors Inc. increased its position in ICON Public by 13.6% in the 4th quarter. FDx Advisors Inc. now owns 3,527 shares of the medical research company's stock valued at $740,000 after acquiring an additional 422 shares during the period. Finally, Transcend Capital Advisors LLC acquired a new stake in ICON Public in the 4th quarter valued at approximately $229,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the company. The Goldman Sachs Group lowered their target price on ICON Public from $180.00 to $160.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. JPMorgan Chase & Co. lowered ICON Public from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $265.00 to $150.00 in a research note on Tuesday, April 29th. Barclays decreased their price target on ICON Public from $165.00 to $155.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Truist Financial decreased their price target on ICON Public from $262.00 to $208.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Finally, Mizuho decreased their price target on ICON Public from $200.00 to $173.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $213.08.
View Our Latest Analysis on ICLR
ICON Public Price Performance
Shares of ICLR traded down $4.79 during trading hours on Thursday, hitting $134.82. 1,262,823 shares of the company were exchanged, compared to its average volume of 1,069,395. The company has a market capitalization of $10.89 billion, a PE ratio of 14.15, a PEG ratio of 1.86 and a beta of 1.15. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The firm has a fifty day simple moving average of $140.78 and a 200-day simple moving average of $179.42. ICON Public Limited has a one year low of $125.10 and a one year high of $347.72.
ICON Public (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical research company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.17 by $0.02. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $2.03 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The company's revenue was down 4.3% compared to the same quarter last year. During the same period last year, the company posted $3.47 EPS. As a group, sell-side analysts predict that ICON Public Limited will post 13.38 earnings per share for the current year.
ICON Public Company Profile
(
Free Report)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Stories
Before you consider ICON Public, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICON Public wasn't on the list.
While ICON Public currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
